Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Drug screening”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1978

Computerized drug-drug interaction screening system.

A pharmacy automated drug interaction screening (PADIS) system is described which detects possible drug interactions by screening patient medication profiles. The data base contains approximately 24,000 drug interaction combinations of drugs marketed in the U.S. and also foreign and investigational drugs that have been implicated to cause drug interactions. It is updated on a monthly basis. The PADIS system operates as a batch run program which screens all patient medication profiles on a daily schedule. A patient drug interaction profile is printed by the computer for use by the pharmacist to suggest alternative therapy to the physician. The computer detects potential drug interactions in approximately 9% of the patients per day at the 635-bed hospital at which the system was developed.

Computers↗
PubMed1979

The significance of drug analysis of sweat in respect to rapid screening for drug abuse.

Morphine and methamphetamine, which are excreted in the sweat, are detected by the use of routine serological and physicochemical techniques for urinary examinations. Screening for drug abuse can be done with the same accuracy of that of urine. Rapid excretion of the drug via kidney (within one day) is followed by a slow but steady excretion of the sweat gland. Methamphetamine given orally in a dose of 10 mg is excreted in the sweat at a constant rate (1.4 microgram/ml). No significant difference of the amount excreted by both systems is found. Alveolar lining seems to prevent the elimination of the volatile methamphetamine via respiration. Not only narcotics and stimulants, but also many alkaloids and barbituarates are excreted in the sweat and detected quantitatively by the same principles. The toxicological analysis of the sweat promises a new scope of forensic investigation.

Forensic Medicine↗
PubMed1978

Screening hallucinogenic drugs II. Systematic study of two behavioral tests.

The effects of hallucinogenic and nonhallucinogenic drugs were studied on two behavioral tests: (1) discriminated Sidman avoidance, using modified Bovet-Gatti profiles, which have been proposed as specific in detecting hallucinogenic activity and (2) a drug discrimination experiment. By the first method, the "hallucinogenic profile" was obtained with both hallucinogenic and nonhallucinogenic drugs and, at least as used here, was not a suitable screening method. In the drug discrimination experiment, data from the present study along with other available evidence suggest the potential value of this method for drug screening procedures.

Animals↗
PubMed1977

A statistical-heuristic methods for automated selection of drugs for screening.

A statistical-heuristic method for selecting drugs for animal screening is developed with molecular structure features as predictors of biological activity. The method is intended to work on large amounts of data over varied structures. A trial of this method on a small data set allows some comparison with more sophisticated pattern recognition methods. Problems connected with interdependence among structure predictors are critical in this method and schemes to eliminate redundancy are reviewed. Alternate sets of structure predictors are considered. The discussion here outlines directions to be taken in the near future.

Animals↗
PubMed1977

Drug usage screening criteria.

Screening criteria for adult use of 40 drugs and pediatric use of 10 drugs are presented. The reasons for presenting the criteria are to (1) document the specific screening criteria applied in a number of drug usage review studies, (2) provide a starting point for other groups wishing to develop criteria for drug usage review and (3) seek comments to be used in improving the criteria.

Drug Labeling↗
PubMed2025

Rapid Generation of Reverse Genetics Systems for Coronavirus Research and High-Throughput Antiviral Screening Using Gibson DNA Assembly.

Coronaviruses (CoVs) pose a significant threat to human health, as demonstrated by the COVID-19 pandemic. The large size of the CoV genome (around 30 kb) represents a major obstacle to the development of reverse genetics systems, which are invaluable for basic research and antiviral drug screening. In this study, we established a rapid and convenient method for generating reverse genetic systems for various CoVs using a bacterial artificial chromosome (BAC) vector and Gibson DNA assembly. Using this system, we constructed infectious cDNA clones of coronaviruses from three genera: human coronavirus 229E (HCoV-229E) of the genus Alphacoronavirus, mouse hepatitis virus A59 (MHV-59) of Betacoronavirus, and porcine deltacoronavirus (PDCoV-Haiti) of Deltacoronavirus. Since beta coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV) represent major human pathogens, we modified the infectious clone of the beta coronavirus MHV-A59 by replacing its NS5a gene with a fluorescent reporter gene to create a system suitable for high-throughput drug screening. Thus, this study provides a practical and cost-effective approach to developing reverse genetics platforms for CoV research and antiviral drug screening.

Reverse Genetics↗
PubMed1977

The hippocampal slice: a system for studying the pharmacology of seizures and for screening anticonvulsant drugs.

Interictal spikes with a configuration similar to that occurring in grand mal epilepsy were generated by the application of penicillin to a hippocampal slice preparation. This slice preparation has potential value for screening anticonvulsant drugs and for studying epileptic activity. The effect of anticonvulsant drugs on seizure activity was tested at concentrations comparable to reported clinical serum concentrations. Phenytoin and diazepam were maximally effective at concentrations of 20 microgram/ml and 3-4 microgram/ml, respectively, in good agreement with their effective concentrations in clinical practice. Phenobarbital was more potent (5 microgram/ml) and mesuximide (50% potent at 80 microgram/ml) was least effective.

Animals↗
PubMed1979

An evaluation of the bovine -- Onchocerca gibsoni, Onchocerca gutturosa model as a tertiary screen for drugs against Onchocerca volvulus in man.

In this trial suramin, diethylcarbamazine, trichlorphon, levamisole, mebendazole, melarsonyl potassiu, Hoechst 33258 and tinidazole were administered to cattle infected with O. gibsoni and O. gutturosa to determine the usefulness of this screen in predicting the effect of drugs in man against. O. volvulus except for melarsonyl potassium which was macrofilarticidal against O. gutturosa but not O. gibsoni when cattle were slaughtered 6 weeks after treatment. It was concluded that cattle infected with O. gibsoni are a satisfactory substitute for chimpanzees infected with O. volvulus, as a tertiary screen for drugs against O. volvulus, but that their use would be restricted to centres in O. gibsoni endemic areas where the necessary facilities and specialised knowledge required to use cattle as experimental animals exist.

Animals↗
PubMed2025

The limitations of small molecule and genetic screening in phenotypic drug discovery.

Phenotypic screens carried out with functional genomics or small molecules have led to novel biological insights, revealed previously unknown targets for drug discovery programs, and provided starting points for the development of first-in-class therapies. Despite being valuable research tools, genetic and compound screening also have significant limitations. This perspective aims to shed a light on those limitations and provide mitigation strategies when available, with a goal of helping phenotypic screening practitioners gain an understanding of how and when to best utilize either approach.

Drug Discovery↗
PubMed1979

Screening for drug and alcohol abuse in a general medical population.

One hundred fifty consecutive, first-visit, general medical patients were simply and inexpensively screened by questionnaire, personal inquiry, and physical examination for drug and alcohol abuse. Seventeen (11.3%) currently used psychoactive drugs, excluding alcohol, and ten (6.7%) used drugs or alcohol on a daily basis to the point that the patient considered it an abuse problem. The majority of the drug and alcohol users recognized their problem on a short questionnaire that was part of a medical intake form. Almost all of the recognized abusers of drugs or alcohol subsequently entered treatment of their problem.

Alcoholism↗
PubMed2026

SCMO: a deep learning model integrating the single-cell resolution TME ecosystem and multi-omics for survival prediction in CRC patients.

BACKGROUND: Colorectal cancer (CRC) remains a leading cause of global cancer mortality, highlighting the need for precise survival prediction to guide clinical decisions. Although tissue-level multi-omics is widely utilized for survival prediction, its limited resolution cannot capture tumor heterogeneity. Single-cell RNA sequencing (scRNA-seq) enables dissection of the tumor microenvironment (TME) at cellular resolution, supporting personalized prognostic assessment. METHODS: We collected 213 CRC scRNA-seq samples and established a CRC-specific TME atlas comprising 339,060 cells. Using this atlas as a reference, we deconvolved bulk RNA-seq data from TCGA-CRC cohort with the EcoTyper algorithm to reconstruct TME features. Clinical, genomic, and transcriptomic data were obtained from the Xena platform; microbial data were sourced from the BIC database. We integrated TME and multi-omics features through a self-normalizing neural network to construct a deep learning model (single-cell resolution TME ecosystem with multi-omics data [SCMO]) for survival prediction. To enhance interpretability, we utilized the Integrated Gradients algorithm and spatial transcriptomic data to analyze multi-omics and TME features. We performed anticancer drug screening with tumor necrosis factor receptor-associated protein 1 (TRAP1), a critical feature according to the Integrated Gradients algorithm, as a potential target. RESULTS: We identified 13 survival-related TME features from the CRC-specific atlas: 12 cell states and one multi-cellular ecosystem. SCMO, which combined TME and multi-omics features, improved survival prediction and outperformed existing methods, achieving a concordance index of 0.762. The SCMO demonstrated robust performance for long-term predictions, achieving areas under the curve (AUCs) of 0.752, 0.772, and 0.869 for 1-, 3-, and 5-year predictions in the training set, with corresponding test set AUCs of 0.639, 0.756, and 0.772. TME features from the SCMO model revealed that ecosystem density increased with CRC malignancy. Multi-omics features included TRAP1 as a potential drug target. Drug screening identified saikosaponin A as a novel TRAP1 inhibitor, and its anticancer activity was validated in vitro. We developed SCMO-Lite, a simplified model incorporating 12 high-attribution-weight multi-omics features, which demonstrated robust risk stratification. CONCLUSIONS: SCMO combines analytical precision with biological interpretability, offering novel insights for oncology survival prediction.

Humans↗
PubMed2026

Endobronchial Ultrasound-Guided Biopsy-Derived Lung Cancer Models: A Platform for Precision Therapy.

BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration is used for clinical diagnosis and staging in patients with lung cancer. Nevertheless, establishing patient-derived preclinical models using needle biopsy samples remains challenging. This study describes the establishment and utility of patient-derived organoid (PDO) from endobronchial ultrasound-guided (EBUS) specimens and EBUS patient-derived xenograft (PDX). METHODS: A total of 175 EBUS specimens were used to establish PDO and PDX. "Stable establishment" organoids with passage numbers of 10 or greater were used for genomic, transcriptome, and pathologic assessment. Drug sensitivity of EBUS organoids and PDX tumors were compared with those of the matched patient. Drug screening was performed using stably established organoid models. RESULTS: We successfully established a total of 20 EBUS organoids: six EBUS-PDOs and 14 EBUS-xenograft derived organoids. These stable cancer organoid models were validated for cancer cell enrichment and pathologic assessment. Pathologic findings, exome, and transcriptome analysis found a high correlation between EBUS organoids and parental samples. EBUS organoids and PDX indicated consistent drug response patterns with their corresponding patients. A drug screening conducted on an EBUS organoid led to the discovery of potent activity of trametinib to a rare MAP2K1 K57N mutation. CONCLUSIONS: EBUS-PDO and -xenograft‒derived organoids are good options to generate stable organoids in patients with advanced stage lung cancer. The models were consistent with the genetic and pathologic features of patient tumors, and the patient's responses to treatment, supporting their utility for novel therapeutic research.

Humans↗